SANDOZ INC. v. UNITED THERAPEUTICS CORPORATION

CourtDistrict Court, D. New Jersey
DecidedDecember 6, 2024
Docket2:19-cv-10170
StatusUnknown

This text of SANDOZ INC. v. UNITED THERAPEUTICS CORPORATION (SANDOZ INC. v. UNITED THERAPEUTICS CORPORATION) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
SANDOZ INC. v. UNITED THERAPEUTICS CORPORATION, (D.N.J. 2024).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

SANDOZ INC. and RAREGEN, LLC, Plaintiffs, Case No. 2:19-cv-10170 (BRM) (JSA) v. OPINION UNITED THERAPUTICS CORP., Defendant.

MARTINOTTI, DISTRICT JUDGE Before this Court is Defendant United Therapeutics Corporation’s (“UTC”) Motion for Stay of Execution of Judgment Pending Appeal Without Bond. (ECF No. 509.) Plaintiff Sandoz Inc. (“Sandoz”) filed an Opposition to the Motion (ECF No. 515), and UTC filed a Reply (ECF No. 517). Having reviewed the submissions filed in connection with the Motion and having declined to hold oral argument pursuant to Federal Rule of Civil Procedure 78(b), for the reasons set forth below and for good cause having been shown, UTC’s Motion for Stay of Execution of Judgment Pending Appeal Without Bond (ECF No. 509) is DENIED. I. BACKGROUND This Court discussed the full factual background of this case in a prior opinion. (ECF No. 503.) For that reason, the Court will discuss only the facts that pertain to this Motion. This Motion is part of a lawsuit initially filed on April 16, 2019. (ECF No. 1.) On March 30, 2022, the Court granted UTC’s Motion for Summary Judgment on Counts I through VI of the Amended Complaint and granted Sandoz’s Motion for Partial Summary Judgment on Count VII as to liability. (ECF No. 383.) The Court held a three-day bench trial beginning on April 29, 2024, and concluding on May 1, 2024, on the amount of damages owed to Sandoz for Count VII. Before the damage award was determined, on October 29, 2024, UTC filed a Motion to Stay Execution of Judgment Pending Appeal without Bond. (ECF No. 509.) On November 1, 2024, the Court ordered a Judgment of $70,600,000 in favor of Sandoz against UTC.1 (ECF Nos. 510, 511.) On the same day, UTC filed its Notice of Appeal. (ECF No. 512.) On November 11, 2024, Sandoz

filed its Notice of Appeal. (ECF No. 513.) On November 13, 2024, Sandoz filed an Opposition to UTC’s Motion. (ECF No. 515.) On November 20, 2024, UTC filed a Reply. (ECF No. 517.) II. LEGAL STANDARD Federal Rule of Civil Procedure 62(b) states a “party may obtain a stay by providing a bond or other security. The stay takes effect when the court approves the bond or other security[.]” Fed. R. Civ. P. 62(b). The 2018 Amendments to the Rule provide that 62(b) “carries forward in modified form the supersedeas bond provisions of Former Rule 62(d). . . . The new rule’s text makes explicit the opportunity to post security in a form other than a bond.” Id. District courts are given discretion in determining whether to waive the bond requirement. See In re Diet Drugs, 582 F.3d 524, 552

(3d Cir. 2009) (“Although Fed. R. Civ. P. 62(d) states that ‘[i]f an appeal is taken, the appellant may obtain a stay by supersedeas bond,’ courts may forego that requirement when there are other means to secure the judgment creditor’s interests.”); Hurley v. Atl. City, 944 F. Supp. 371, 374 (D.N.J. 1996) (citing Dillon v. City of Chicago, 866 F.2d 902, 904 (7th Cir. 1988)); see, e.g., Arban v. W. Pub. Corp., 345 F.3d 390, 409 (6th Cir. 2003) (stating Rule 62(d), which speaks to stays granted as a matter of right, does not inhibit district courts from granting stays pursuant to their

1 The time to post a bond was set to expire on December 1, 2024. A status conference via telephone was held on November 27, 2024 in anticipation of this deadline. Both parties consented to an extension of the automatic stay of proceedings to enforce the Court’s November 1, 2024 Judgment (ECF No. 511) to December 15, 2024 pursuant to Federal Rule of Civil Procedure 62(a). (ECF No. 525). discretion); Fed. Prescription Serv., Inc. v. Am. Pharm. Ass’n, 636 F.2d 755, 759 (D.C. Cir. 1980) (same); see also Montalvo v. Larchmont Farms, Inc., 2011 WL 6303247, at *1 (D.N.J. Dec. 15, 2011) (“[D]istrict courts within the Third Circuit have found that they have discretion under Rule 62(d) to waive the bond requirement in whole or in part.”) (citing Church & Dwight Co. v. Abbott Labs., 2009 WL 2230941, at *14 (D.N.J. July 23, 2009)).

“Courts exercise this discretion ‘where there exists an alternative means of securing the judgment’ and there ‘are exceptional circumstances.’” Ingenieria, Maquinaria Y Equipos de Colombia S.A. v. Aviation Tech. & Turbine Serv., Inc., Civ. A. No. 17-3624, 2018 WL 10149715, at *1 (D.N.J. Apr. 9, 2018) (internal citations omitted). Exceptional means can be determined via the Dillon factors, as set forth in Dillon v. City of Chicago, 866 F.2d at 904–05. See Ingenieria, 2018 WL 10149715, at *2; Hilburn v. Bayonne Parking Auth., Civ. A. No. 07-5211, 2013 WL 1721648, at *2 (D.N.J. Apr. 19, 2013); Grant v. Omni Health Care Systems of NJ, Inc., No. 08–306, 2010 U.S. Dist. LEXIS 82963 at *2 (D.N.J. Aug. 13, 2010); Church, 2009 WL 2230941 at *41–42. In addition, courts have held that, beyond needing an alternative means to secure the

judgment, the posting of the bond must also be impossible or impracticable. See Ingeniera, 2018 WL 10149715 at *2.; Hilburn, WL 1721648, at *2 (“To show waiver of bond is appropriate, ‘it is the appellant’s burden to demonstrate objectively that posting a full bond is impossible or impracticable; likewise it is the appellant’s duty to propose a plan that will provide adequate (or as adequate as possible) security for the appellee.’”) (citing AMG Nat’l Trust Bank v. Ries, Civ. A. No. 06–4337, 2008 WL 2312352, at *1 (E.D. Pa. June 4, 2008), aff’d in part and remanded, 319 F. App’x 90 (3d Cir. 2008)). There are five factors courts rely upon in determining whether to waive the bond requirement: (1) the complexity of the collection process; (2) the amount of time required to obtain a judgment after it is affirmed on appeal; (3) the degree of confidence that the district court has in the availability of funds to pay the judgment . . . ; (4) whether the defendant’s ability to pay the judgment is so plain that the cost of a bond would be a waste of money . . . ; and (5) whether the defendant is in such a precarious financial situation that the requirement to post a bond would place other creditors of the defendant in an insecure position. . . . Dillon, 866 F.2d at 904–05; see Sabre GLBL, Inc. v. Shan, 2018 WL 4350279, at *2 (D.N.J. Sept. 12, 2018) (noting “courts in this district” apply “the Dillon factors” in this context). III. DECISION UTC argues the first four Dillon factors have been met and “weigh in favor of granting UTC’s request” to avoid filing a supersedeas bond. (ECF No. 509 at 3.) UTC claims the fifth factor is irrelevant as its “financial situation is anything but ‘precarious,’” and it “undoubtedly has sufficient funds to pay a judgment within the $65 million to $81 million range submitted by the parties.” (Id.) Further, UTC claims “in the event the Judgment is sustained on appeal, Sandoz will be able to promptly collect the amount of the Judgment[.]” (Id.) Sandoz disagrees, stating “UTC’s confidence in its current ability to pay . . .

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Diet Drugs
582 F.3d 524 (Third Circuit, 2009)
Hurley v. Atlantic City Police Department
944 F. Supp. 371 (D. New Jersey, 1996)
Ryan v. Asbestos Workers Union Local 42 Pension Fun
27 F. App'x 100 (Third Circuit, 2002)
AMG Natl Trust Bank v. Stephen Ries
319 F. App'x 90 (Third Circuit, 2008)
Tunis Bros. v. Ford Motor Co.
952 F.2d 715 (Third Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
SANDOZ INC. v. UNITED THERAPEUTICS CORPORATION, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sandoz-inc-v-united-therapeutics-corporation-njd-2024.